Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/9/2010

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the third quarter ended September 30, 2010.

Regarding the Company's ongoing review of strategic alternatives, Ronald Martell, chief executive officer of Poniard, said: "Poniard is actively focused on the execution of strategic alternatives aimed at optimizing the value of the Company and of our lead program, picoplatin.  This effort is our highest priority, and one for which the management team and its advisors are working diligently to achieve a successful outcome."

Third Quarter 2010 Unaudited Financial ResultsThe Company reported a net loss of $6.4 million ($0.13 diluted loss per share on a loss applicable to common shares of $6.5 million) for the quarter ended September 30, 2010, compared with a net loss of $9.9 million ($0.29 diluted loss per share on a loss applicable to common shares of $10.0 million) for the quarter ended September 30, 2009. For the first nine months of 2010, the net loss was $24.9 million ($0.55 diluted loss per share on a loss applicable to common shares of $25.6 million), compared to a net loss of $32.5 million ($0.95 diluted loss per share on a loss applicable to common shares of $32.9 million) for the same period in 2009.

Total operating expenses for the quarter ended September 30, 2010 were $6.0 million compared with $9.2 million for the quarter ended September 30, 2009. Year to date, total operating expenses were $23.2 million compared to $30.5 million for the first nine months of 2009.

Research and development expenses were $0.9 million for the quarter ended September 30, 2010, compared with $5.1 million for the quarter ended September 30, 2009. Year to date, research and development expenses were
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Research and Markets  has ... Pralmorelin" report to their offering. Global ... data on Pralmorelin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... ANN ARBOR, Mich. and ... a non-profit corporation established to bring cutting-edge next-generation ... trials to cancer patients, today announced a collaboration ... molecular capabilities to characterize patient tissue samples from ... be sensitive or resistant to TESARO,s TSR-011.  This may ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... Corp., formerly known as InstaCare Corp., (OTCQB: ISCRD), a ... the chronically ill, a leading fulfillment provider of direct ... revolutionary cell phone centric e -health products and ... Dividend will be Ex-Dividend to all shareholders of record ...
... ENDP ) today announced that David Holveck, president ... Morgan 30th Annual Healthcare Conference on Monday, January 9, 2012 ... the Westin St. Francis in San Francisco, Calif. ... be available on the company,s website at http://www.endo.com/ .  ...
Cached Medicine Technology:Decision Diagnostic Corp. Clarifies 10% Stock Dividend, Announces Patent Enforcement Strategy 2
(Date:8/21/2014)... 21, 2014 Only 20 percent of healthcare ... Affordable Care Act according to a new report . ... responding to a request from Smart Data pioneer ... lead providers to violate privacy laws in many states. , ... many hospitals and clinics are failing to do so in ...
(Date:8/21/2014)... 21, 2014 Inc. magazine ranked Centurion ... 500|5000, an exclusive ranking of the nation's fastest-growing private ... the most important segment of the economy—America’s independent entrepreneurs. ... LinkedIn, Zillow, and many other well-known names gained early ... is proud to have been named to the Inc. ...
(Date:8/21/2014)... Houston, TX (PRWEB) August 21, 2014 Sometimes you ... destiny. , In his new book “From Zero to a Hundred: ... police officer, shares his story of surviving a broken family, a ... “Adversity brings affirmation of who you were created to be,” Roy ... zero,’ which is why I know my purpose today of helping ...
(Date:8/21/2014)... CQIIP, Continuous Quality Immunization Improvement ... Control and Prevention and the Department of Defense. ... the immunization standards and are administered in accordance ... on Immunizations. , ACC chose to adopt the ... place to protect patients, improve efficiency, and increase ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... aging interventions and addressing the challenges of ... concept, OncoFinder, for signalome-wide pathway analysis. ... robust cross-platform analysis of gene expression data ... research, published in the journal Frontiers in ...
Breaking Medicine News(10 mins):Health News:Report: Only 20 Percent of Healthcare Providers Meet ACA Requirement 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:ACC Health Raises the Bar Again by Completing the CQIIP Certification Program 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... JUPITER, FL, May 28, 2009 Current tests to identify specific ... diseases (such as mad cow) in animals and humans, can ... results a time-lag that may put human populations at ... Research Institute,s Florida campus have developed a new method that ...
... Inc. (NYSE: DVA ) announced today ... the Company,s Board of Directors. (Logo: ... former President of American Express International, Japan, Asia-Pacific, ... the Consumer Card business across 12 countries, heading ...
... Annoying seasonal allergies is now a year round threat. ... to nest in the home. Indoor air pollution is ... chemicals, synthetic materials and impurities. To expel these year ... to home ventilation and eliminates allergens.The EZ Breathe system ...
... The best respiratory protection is useless if it ... series, Draeger dedicated special attention to ensuring that the ... comfort of the wearer was maximized. While offering extremely ... been compromised. (Photo: http://www.newscom.com/cgi-bin/prnh/20090528/NE24067 ...
... Darwin National,Assurance Company, a member company of Allied ... ), today announced that Becky Cox has been ... Ms. Cox will,be responsible for the continued development ... Fred Bautista, Vice,President, Business Development, Healthcare. , ...
... of overdose, and potential liver damage, is still too ... -- One month after mandating stricter warning labels about ... U.S. regulators are contemplating even tougher standards. , Advisers ... late next month to review a new agency report ...
Cached Medicine News:Health News:Scripps Florida scientists devise accelerated method to determine infectious prion strains 2Health News:Scripps Florida scientists devise accelerated method to determine infectious prion strains 3Health News:Pamela M. Arway Joins DaVita Board of Directors 2Health News:EZ Breathe(R) Home Ventilation System Expels Allergens, Moisture and Smells 2Health News:Comfort Matters - The new Draeger Series of Filtering Facepiece Respirators Demonstrate Exceptional Wearer Comfort 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 3Health News:FDA Report Urges Tougher Acetaminophen Warning 2
... Solution is the ... povidone-iodine. It is a ... kills gram-positive and gram-negative ... organisms), as well as ...
... Aplicare's disposable 1-ounce pouches are designed for ... waste. They are used in nursing homes, ... rooms and many other hospital departments. This ... is a mild antiseptic, germicidal and cleansing ...
... Aplicare's Iodine Scrub is a gentle ... formulated to prevent dryness. Povidone Iodine is ... gram-negative and gram-positive bacteria, fungi, viruses, protozoa ... lather; the first step in patient pre-operative ...
... Iodine Scrub is a gentle and effective ... prevent dryness. Povidone Iodine is known to ... gram-positive bacteria, fungi, viruses, protozoa and yeasts. ... first step in patient pre-operative prepping, as ...
Medicine Products: